Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Enspryng ™(satralizumab-mwge)…
Press
The U.S. Food and Drug Administration today approved Uplizna (inebilizumab-cdon) injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult…
Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved SOLIRIS® (eculizumab) for the treatment of neuromyelitis optica spectrum disorder (NMOSD)…
WALTHAM, Mass. and BEVERLY HILLS, Calif., March 30, 2021 /PRNewswire/ – CorEvitas and The Guthy-Jackson Charitable Foundation (GJCF) are excited to announce plans for launching the SPHERES (Synergy of Prospective Health…
Learn about the four main advocacy groups in NMOSD, and their incredible origin stories. Click here to view the full article.
Satralizumab represents a potential new approach to treating neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating disease often misdiagnosed as multiple sclerosis (MS)… Click here…
Featured Videos
